Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -92.20% is 41% below its 2-year average of -65.45%, near the low end of its 2-year range (-122.75%–-13.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.31% below its 12-month average of -86.73%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -92.20%.
RETURN ON EQUITY (ROE)
-92.20%
RETURN ON EQUITY (ROE) AVG TTM
-86.73%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.31%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-129.30%
vs the sector median at left
Kyverna Therapeutics, Inc.
Market Cap
$376.93M
Return on Equity (ROE)
-92.20%
TTM Avg
-86.73%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$378.03M
Return on Equity (ROE)
-54.29%
TTM Avg
-32.16%
3Y Avg
-17.89%
5Y Avg
-29.83%
Market Cap
$381.75M
Return on Equity (ROE)
-65.99%
TTM Avg
-51.25%
3Y Avg
-81.12%
5Y Avg
-81.12%
Market Cap
$370.48M
Return on Equity (ROE)
-38.57%
TTM Avg
-80.22%
3Y Avg
-181.01%
5Y Avg
-130.47%
Market Cap
$355.99M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$354.37M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$354.19M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$352.93M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$405.52M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $376.93M | -92.20% | -86.73% | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $378.03M | -54.29% | -32.16% | -17.89% | -29.83% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $381.75M | -65.99% | -51.25% | -81.12% | -81.12% |
| Canopy Growth Corporation (CGC)vs › | $370.48M | -38.57% | -80.22% | -181.01% | -130.47% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $355.99M | -200.64% | -134.16% | -101.12% | -54.69% |
| Ocugen, Inc. (OCGN)vs › | $354.37M | N/A | 187.63% | 25.60% | -9.96% |
| Embecta Corp. (EMBC)vs › | $354.19M | N/A | -12.63% | -14.73% | 14.28% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $352.93M | -7.66% | -10.18% | 260.20% | 144.75% |
| Neurogene Inc. (NGNE)vs › | $405.52M | -51.17% | -29.16% | -33.45% | -16.04% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $349.23M | -62.56% | -108.31% | -79.06% | -57.33% |
ROE
-92.2%
ROA
-69.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -92.20% |
| 2026-03-31 | -79.97% |
| 2025-12-31 | -69.45% |
| 2025-09-30 | -105.95% |
| 2025-06-30 | -86.07% |
| 2025-03-31 | -64.92% |
| 2024-12-31 | -37.82% |
| 2024-09-30 | -27.75% |
| 2024-06-30 | -19.48% |
| 2024-03-31 | -13.64% |
| 2023-12-31 | -122.75% |
